Dr. Woyach Discusses Progression on Ibrutinib With the Acquisition of Resistance Mutations

(1:17)

Dr. Woyach on the Results of the ELEVATE-TN Trial

(55)

Dr. Woyach on the Role of Chemoimmunotherapy in CLL

(1:25)

Dr. Woyach Discusses Progression on Ibrutinib With the Acquisition of Resistance Mutations

(1:31)

Dr. Woyach on Using Ibrutinib in Combination Therapies

(1:53)

Dr. Woyach Discusses the Efficacy Findings from the RESONATE Trial

(28)

Dr. Woyach on Treatment Challenges in CLL

(1:17)

Dr. Woyach on Ibrutinib Resistance in CLL

(1:47)

Cystoid Macular Edema

(1:52:35)

Seniors: How I Regained My Coordination and Balance!

(3:22)

Jennifer Woyach, MD, Highlights Novel CLL Therapies Presented at ASH 2023

(9:47)

SDB Ethel Browne Harvey Postdoctoral Seminar Series - Yuchuan Miao and Kari Price

(57:35)

2021 Pelotonia-Funded Researcher of the Year Award, awarded to Jennifer Woyach, MD

(2:20)

Lymphocytosis (Medical Condition)

(32)

Dr. Wierda on Ibrutinib Resistance in CLL

(2:11)

Dr. Woyach on the Role of Acalabrutinib in CLL

(1:39)

Dr. Woyach Discusses Peripheral Lymphocytosis in Patients with CLL Taking Ibrutinib

(1:26)

Dr. Woyach Discusses Efficacy Findings from the RESONATE Trial

(40)

Dr. Woyach on BTK Inhibition and the Mechanism of Action of Ibrutinib

(1:17)

Dr. Woyach on Ibrutinib and Peripheral Lymphocytosis in Patients with Chronic Lymphocytic Leukemia

(1:16)

Dr. Woyach on the Role of Small Molecule Inhibitors in CLL

(1:8)

Dr. Woyach on Ibrutinib Regimens in Frontline CLL

(1:6)

Dr. Woyach on Clinical Trials Examining Novel Triplets in CLL

(1:21)

Dr. Woyach on the Safety of Acalabrutinib Versus Ibrutinib in CLL

(1:3)

Meet Jennifer Woyach, MD, Hematologist at the OSUCCC – James

(1:34)

Dr. Woyach on Remaining Sequencing Questions in CLL

(1:28)